이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Strides Pharma Science 과거 수익 실적

과거 기준 확인 0/6

Strides Pharma Science의 수입은 연평균 -48%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 17%의 비율로 증가했습니다. 매출은 연평균 6.4%의 비율로 증가해 왔습니다.

주요 정보

-48.0%

수익 성장률

-47.9%

EPS 성장률

Pharmaceuticals 산업 성장	17.5%
매출 성장률	6.4%
자기자본 수익률	-7.2%
순이익	-3.1%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11

Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Dec 28

Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10

Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?

Nov 25

수익 및 비용 분석

Strides Pharma Science 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NSEI:STAR 수익, 비용 및 수입 (INR Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	40,511	-1,248	7,511
31 Dec 23	39,535	-1,525	7,642
30 Sep 23	37,806	-2,280	7,607
30 Jun 23	36,783	-924	7,159
31 Mar 23	36,884	-2,212	7,686
31 Dec 22	35,680	-1,824	7,395
30 Sep 22	34,976	-2,241	7,385
30 Jun 22	33,220	-3,909	6,692
31 Mar 22	30,703	-4,602	6,728
31 Dec 21	31,127	-4,425	6,636
30 Sep 21	31,504	-2,830	6,120
30 Jun 21	32,224	-543	5,817
31 Mar 21	33,159	2,545	5,704
31 Dec 20	30,260	28	5,359
30 Sep 20	29,264	589	5,192
30 Jun 20	28,480	1,266	4,906
31 Mar 20	27,520	492	4,579
31 Dec 19	35,828	2,859	5,872
30 Sep 19	34,203	2,169	5,536
30 Jun 19	32,248	745	5,346
31 Mar 19	21,784	840	3,707
31 Dec 18	28,547	-93	5,349
30 Sep 18	28,090	139	5,420
30 Jun 18	28,451	415	4,363
31 Mar 18	28,451	544	5,334
31 Dec 17	35,810	1,050	6,921
30 Sep 17	36,593	1,124	6,931
30 Jun 17	35,357	1,712	6,064
31 Mar 17	27,554	2,335	4,860
31 Dec 16	37,237	2,840	6,984
30 Sep 16	36,573	2,410	6,760
30 Jun 16	34,189	2,168	6,061
31 Mar 16	28,622	1,317	4,026
31 Dec 15	24,901	1,152	5,508
30 Sep 15	12,962	860	3,367
30 Jun 15	12,105	244	3,206
31 Mar 15	11,958	16	1,994
31 Mar 14	10,728	-1,867	2,329

양질의 수익: STAR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: STAR 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: STAR 은(는) 수익성이 없으며 지난 5년 동안 연간 48% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 STAR 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: STAR 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 18% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: STAR 현재 수익성이 없기 때문에 마이너스 자본 수익률( -7.17% )을 갖습니다.

Strides Pharma Science 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Recent updates

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Executive Changes

Founder & Non-Executive Chairman recently bought ₹50m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target decreased to ₹735

Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021)

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹14m worth of stock

First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021)

Less than half of directors are independent

Upcoming dividend of ₹2.50 per share

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Insider recently sold ₹2.8m worth of stock

Chief Human Resource Officer recently sold ₹4.1m worth of stock

TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India

Full year 2021 earnings released: EPS ₹28.40 (vs ₹5.49 in FY 2020)

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)